Quest Diagnostics Incorporated (DGX) Financial Statements
Quest Diagnostics Incorporated (DGX) reported trailing twelve-month revenue of $11.8B (up 9.1% year on year) and net income of $1.1B as of 2026-09-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $1.4B.
Source: SEC EDGAR filings · figures as of 2026-09-30 · read by EquiReason
DGXQuest Diagnostics IncorporatedFollow DGX — free
—
Price chart with a free account
- Market cap
- 26.6B
- P/E TTM
- 24.1
- Dividend yield
- 1.4%
- 52-week
- —
- Next earnings
- 8 Feb, in 107 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Sep 26.
| Line | FY2009 Dec 09 | FY2010 Dec 10 | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Sep 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.46 | 7.26 | 7.39 | 7.38 | 7.15 | 7.44 | 7.49 | 7.21 | 7.40 | 7.53 | 7.73 | 9.44 | 10.79 | 9.88 | 9.25 | 9.87 | 11.04 | 11.84 | |
| Gross profit | 3.13 | 3.05 | 3.03 | 3.02 | 2.82 | 2.80 | 2.84 | 2.90 | 2.68 | 2.61 | 2.69 | 3.63 | 4.21 | 3.43 | 3.05 | 3.24 | 3.67 | 3.92 | |
| Operating income | 1.36 | 1.28 | 0.99 | 1.20 | 1.48 | 0.98 | 1.40 | 1.28 | 1.17 | 1.10 | 1.23 | 1.97 | 2.38 | 1.43 | 1.26 | 1.35 | 1.56 | 1.72 | |
| Pre-tax income | 1.23 | 1.17 | 0.85 | 1.07 | 1.32 | 0.82 | 1.10 | 1.09 | 1.03 | 0.93 | 1.08 | 1.88 | 2.60 | 1.24 | 1.13 | 1.18 | 1.32 | 1.49 | |
| Income tax | 0.46 | 0.43 | 0.36 | 0.40 | 0.50 | 0.26 | 0.37 | 0.43 | 0.24 | 0.18 | 0.25 | 0.46 | 0.60 | 0.26 | 0.25 | 0.27 | 0.31 | 0.34 | |
| Net income | 0.73 | 0.72 | 0.47 | 0.56 | 0.85 | 0.56 | 0.71 | 0.65 | 0.77 | 0.74 | 0.86 | 1.43 | 2.00 | 0.95 | 0.85 | 0.87 | 0.99 | 1.13 | |
| Diluted EPS ($) | 3.87 | 4.05 | 2.92 | 3.46 | 5.54 | 3.81 | 4.87 | 4.51 | 5.50 | 5.29 | 6.28 | 10.47 | 15.55 | 7.97 | 7.49 | 7.69 | 8.75 | 10.04 | |
| Diluted shares (bn) | — | 0.177 | 0.160 | 0.160 | 0.153 | 0.145 | 0.145 | 0.142 | 0.140 | 0.139 | 0.136 | 0.136 | 0.128 | 0.118 | 0.113 | 0.113 | 0.113 | — |
USD billions · SEC XBRL
Quest Diagnostics Incorporated — questions
- What is Quest Diagnostics Incorporated's revenue?
- $11.8B over the twelve months to 2026-09-30, up 9.1% year on year, from its 10-Q and 10-K filings.
- What is Quest Diagnostics Incorporated's net income?
- $1.1B over the twelve months to 2026-09-30.
- What is Quest Diagnostics Incorporated's free cash flow?
- $1.4B over the twelve months to 2026-09-30.
- What are Quest Diagnostics Incorporated's diluted earnings per share?
- $10.04 over the twelve months to 2026-09-30.
Every figure on this page comes from Quest Diagnostics Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.